Literature DB >> 16364765

Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population.

Jiaoyang Yin1, Ulla Vogel, Li Guo, Yegang Ma, Huiwen Wang.   

Abstract

The ERCC1 (Excision Repair Cross Complementation Group 1) gene is involved in the nucleotide excision repair pathway. This study was designed to examine whether ERCC1 Asn118Asn (G19007A) polymorphism, which has been associated with risk of some cancers among Caucasians, may be associated with risk of lung cancer in a Chinese population. ERCC1 Asn118Asn (G19007A) genotypes were determined in DNA samples from 151 cases and 143 controls. The distribution of genotypes between cases and controls was not associated with an increased risk of lung cancer (AA versus GG: adjusted OR (odds ratio) = 1.41, 95% CI (confidence interval) = 0.76-2.59; AG versus GG: adjusted OR = 0.78, 95% CI = 0.47-1.29; and AA + AG versus GG: adjusted OR = 0.93, 95% CI = 0.73-1.19). The frequency A (0.20) of the A-allele was significantly lower among these Chinese controls than in the Caucasian control populations (A = 0.54-0.65) (All P < 0.001). No statistically significant effects of age, histological subtype or smoking were found. These findings suggest that ERCC1 Asn118Asn (G19007A) polymorphism may play a limited role for lung cancer in this Chinese population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16364765     DOI: 10.1016/j.cancergencyto.2005.07.003

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population.

Authors:  Nathan R Jones; Thomas E Spratt; Arthur S Berg; Joshua E Muscat; Philip Lazarus; Carla J Gallagher
Journal:  Cancer Epidemiol       Date:  2010-09-21       Impact factor: 2.984

2.  Nucleotide excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African Americans.

Authors:  Jeffrey S Chang; Margaret R Wrensch; Helen M Hansen; Jennette D Sison; Melinda C Aldrich; Charles P Quesenberry; Michael F Seldin; Karl T Kelsey; Rick A Kittles; Gabriel Silva; John K Wiencke
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

Review 3.  Genetic susceptibility to lung cancer--light at the end of the tunnel?

Authors:  Ariela L Marshall; David C Christiani
Journal:  Carcinogenesis       Date:  2013-01-24       Impact factor: 4.944

4.  ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.

Authors:  Zhao-Hui Huang; Dong Hua; Xiang Du; Li-Hua Li; Yong Mao; Zhi-Hui Liu; Ming-Xu Song; Xi-Ke Zhou
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

Review 5.  Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis.

Authors:  Chikako Kiyohara; Kouichi Yoshimasu
Journal:  Int J Med Sci       Date:  2007-02-01       Impact factor: 3.738

Review 6.  Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis.

Authors:  Jinhong Zhu; Rui-Xi Hua; Jing Jiang; Li-Qin Zhao; Xiuwei Sun; Jinwei Luan; Yaoguo Lang; Yanqi Sun; Kun Shang; Shiyun Peng; Jianqun Ma
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

7.  Association between rs735482 polymorphism and risk of cancer: A meta-analysis of 10 case-control studies.

Authors:  Shilin Xue; Wenya Shen; Jianning Cai; Jinhai Jia; Dan Zhao; Shan Zhang; Xiujun Zhao; Ning Ma; Wenjuan Wang; Bingshuang Wang; Xiaolin Zhang; Xuehui Liu
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

8.  ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.

Authors:  Alec Vaezi; Chelsea H Feldman; Laura J Niedernhofer
Journal:  Pharmgenomics Pers Med       Date:  2011-07-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.